Parkinson's disease: progression and mortality in the L-DOPA era

Adv Neurol. 1996:69:3-11.

Authors

A Di Rocco¹, S P Molinari, B Kollmeier, M D Yahr

Affiliation

¹ Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA.

PMID: 8615142

No abstract available

Publication types

Clinical Trial

MeSH terms

Adult
Age of Onset
Aged
Aged, 80 and over
Antiparkinson Agents / adverse effects
Antiparkinson Agents / therapeutic use*
Cause of Death
Dementia / complications
Disease Progression
Dyskinesia, Drug-Induced / complications
Dyskinesia, Drug-Induced / epidemiology
Dyskinesia, Drug-Induced / physiopathology
Female
Follow-Up Studies
Humans
Hypotension, Orthostatic / complications
Hypotension, Orthostatic / physiopathology
Levodopa / adverse effects
Levodopa / therapeutic use*
Life Expectancy
Male
Middle Aged
Parkinson Disease / drug therapy*
Parkinson Disease / mortality*
Parkinson Disease / physiopathology
Survival Analysis

Substances

Antiparkinson Agents
Levodopa